Skip to main content Skip to search Skip to main navigation

ICH: Press Release ICH-Assembly Meeting

The ICH published a press release on June 20, regarding a face-to-face meeting on June 12 and 13, 2023, in Vancouver, Canada. Meetings of 14 working groups, the ICH Management Committee and the MedDRA Management Committee were also held during that time.

New Areas of ICH Harmonisation

Three new areas of harmonisation were defined at the meeting:

  • “General Considerations for Patient Preference Studies” – Efficacy guideline with considerations for a systematic approach to planning, conducting, analyzing, and processing patient preference studies when they contain important advanced information for evaluating products or inform drug development and related decisions.
  • “Nonclinical Safety Studies for Oligonucleotide-based Therapeutics” – Safety Guideline that communicates regulatory requirements for non-clinical safety evaluations of various oligonucleotide-based treatment options through general understanding.
  • “Bioequivalence for Modified-Release Products” – Multidisciplinary Guideline that represents an important step towards the harmonisation of bioequivalence standards for more complex dosage forms. The harmonised elements of the M13 Guideline series are transferable.

In a later step, the starting timeframe will be defined.

Additional results of the meeting are:

  • The formation of a new ICH “Cell and Gene Therapies” Discussion Group (CGTDG), providing a technical communication forum for issues related to ICH harmonisation efforts in the area of CGT products.
  • A new ICH Reflection Paper for the “International Harmonisation of Real-World Evidence Terminology and Convergence of General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with a Focus on Effectiveness of Medicines”.
  • They noted significant milestones since the last ICH meeting, for example the adoptation of the revised ICH Q9 (R1) Guideline on “Quality Risk Management” in January 2023.

The press release also states that the African Authority EDA (Egypt) has joined ICH as a Member and NAFDAC (Nigeria) as an ICH Observer.


Source

ICH: Press Release

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is First Air Verified and Monitored During Aseptic Process Qualification?

How is First Air Verified and Monitored During Aseptic Process Qualification?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part I: Supplier Management

Outsourced Activities in the GDP Environment Part I: Supplier Management

Supplier management is the systematic management of a company´s relationship with its suppliers. It encompasses supplier qualification and customer audits as described in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

On 14 August 2026, the US Food and Drug Administration (FDA) announced the publication of a new draft guidance document entitled ‘Container Closure Systems for Human Drugs and Biological Products’.

Read more
FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Previous
Next